KURA ONCOLOGY, INC. Net Change in Cash
KURA ONCOLOGY, INC. (KURA) reported Net Change in Cash of -$78.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$110.02M.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$173.19M, a 4235.46% decline year-over-year.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $4.19M.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$24.74M.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$75.36M, a 140.27% decline from fiscal 2024.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $187.14M.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$14.48M.
- KURA ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$38.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$78.86M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$110.02M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$75.36M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$129.18M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$142.51M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$173.19M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $187.14M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $12.16M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $7.87M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $4.19M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$14.48M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | -$23.06M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$2.68M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$24.74M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$38.87M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $265.00K 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$51.41M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$56.84M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$234.82M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$286.31M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$286.52M 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | -$214.66M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $299.57M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $51.03M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $108.83M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $7.89M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $10.02M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $38.62M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $105.96M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $1.66M 10-Q · filed 2020-05-04 | |||
| 2018-12-31 | $4.69M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $9.13M 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $1.71M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |